• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nature: IFITM3 restricts the morbidity and mortality associated with influenza

tetano

Editor, Senior Moderator
IFITM3 restricts the morbidity and mortality associated with influenza

Aaron R. Everitt,
Simon Clare,
Thomas Pertel,
Sinu P. John,
Rachael S. Wash,
Sarah E. Smith,
Christopher R. Chin,
Eric M. Feeley,
Jennifer S. Sims,
David J. Adams,
Helen M. Wise,
Leanne Kane,
David Goulding,
Paul Digard,
Verneri Anttila,
J. Kenneth Baillie,
Tim S. Walsh,
David A. Hume,
Aarno Palotie,
Yali Xue,
Vincenza Colonna,
Chris Tyler-Smith,
Jake Dunning,
Stephen B. Gordon,
The GenISIS Investigators
et al.

Affiliations
Contributions
Corresponding authors

Nature
(2012)
doi:10.1038/nature10921

Received
07 September 2011
Accepted
08 February 2012
Published online
25 March 2012



The 2009 H1N1 influenza pandemic showed the speed with which a novel respiratory virus can spread and the ability of a generally mild infection to induce severe morbidity and mortality in a subset of the population. Recent in vitro studies show that the interferon-inducible transmembrane (IFITM) protein family members potently restrict the replication of multiple pathogenic viruses1, 2, 3, 4, 5, 6, 7. Both the magnitude and breadth of the IFITM proteins? in vitro effects suggest that they are critical for intrinsic resistance to such viruses, including influenza viruses. Using a knockout mouse model8, we now test this hypothesis directly and find that IFITM3 is essential for defending the host against influenza A virus in vivo. Mice lacking Ifitm3 display fulminant viral pneumonia when challenged with a normally low-pathogenicity influenza virus, mirroring the destruction inflicted by the highly pathogenic 1918 ?Spanish? influenza9, 10. Similar increased viral replication is seen in vitro, with protection rescued by the re-introduction of Ifitm3. To test the role of IFITM3 in human influenza virus infection, we assessed the IFITM3 alleles of individuals hospitalized with seasonal or pandemic influenza H1N1/09 viruses. We find that a statistically significant number of hospitalized subjects show enrichment for a minor IFITM3 allele (SNP rs12252-C) that alters a splice acceptor site, and functional assays show the minor CC genotype IFITM3 has reduced influenza virus restriction in vitro. Together these data reveal that the action of a single intrinsic immune effector, IFITM3, profoundly alters the course of influenza virus infection in mouse and humans.

http://www.nature.com/nature/journal/vaop/ncurrent/full/nature10921.html
 
Back
Top Bottom